Skip to main content
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc. — Investor Relations & Filings

Ticker · VERA ISIN · US92337R1014 US Professional, scientific and technical activities
Open in API
Filings indexed 418 across all filing types
Latest filing 2022-05-16 Earnings Release
Country US United States of America
Listing US VERA

About Vera Therapeutics, Inc.

https://veratx.com/

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological and rare diseases. The company's mission is to change the standard of care and improve patients' lives. Its lead product candidate is atacicept, a novel biologic molecule being developed for the treatment of IgA nephropathy (IgAN), a progressive autoimmune kidney disease. Vera Therapeutics aims to advance its pipeline of innovative therapies to address significant unmet medical needs within immunology.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing financial results for the quarter ended March 31, 2022, and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length is 3592 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, initial announcements of quarterly financial results in a press release format correspond to an Earnings Release (ER). Therefore, the filing type is Earnings Release (ER).
2022-05-16 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a 'SCHEDULE 14A INFORMATION' and a 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is marked as 'Definitive Additional Materials' related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document length is short (1127 characters), consistent with additional proxy materials rather than a full report. Therefore, this document fits the category of Proxy Solicitation & Information Statement (PSI).
2022-04-14 English
DEF14A
Proxy Solicitation & Information Statement
2022-04-14 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 7, 2022, reporting a change in the company's board of directors and senior management. It details the resignation of a director and chair of the board, and the appointment of a new director and chair, including compensation arrangements. There are no financial statements or detailed financial performance data. The content fits the category of announcements related to changes in board or management personnel. Therefore, the document is best classified as Board/Management Information (MANG). The document length (5800 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2022-04-12 English
AMENDMENT NO.1
Major Shareholding Notification
2022-04-07 English
SC 13D/A
Major Shareholding Notification
2022-04-05 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.